UK biotech financing hit a five-year high in the second quarter of 2026 with total equity financing reaching £2.11bn, including a record £2.05bn in venture capital, according to new figures from the BioIndustry Association (BIA).
Q2 2026 was dominated by Isomorphic Labs’ landmark £1.6bn Series B round. Even excluding this record financing, UK biotech companies secured £498m in venture capital during Q2 – almost double the £279m raised in Q2 2025.
Building on the positive momentum seen in Q1, Q2 2026 delivered the strongest quarter for UK biotech venture investment in the past five years. The UK also strengthened its position as Europe’s leading biotech investment destination, accounting for 61% of Europe’s £3.3bn venture capital total during the quarter.
Seed investment remained resilient, with eight seed deals completed during the quarter and rounds averaging £6.4m as companies bypassed smaller historic structures to raise substantial first financings.
Series A- and B+-stage companies each raised £190m and £225m respectively, and the critical £10m to £25m funding bracket saw an uptick.
While UK public markets showed modest signs of improvement, they continued to trail the strength of private financing.
Follow-on financing reached £58m in Q2 2026 – a 61% increase from £36m in Q1 and significantly above the £15m raised in Q2 2025.
However, no UK biotech IPOs have occurred so far in 2026 and there was no follow-on activity by UK biotech companies listed on NASDAQ.
The report also points to growing institutional support for the sector, such as the British Business Bank has deploying capital at an increased pace to venture funds. Its £25m investment into Alchemab – its largest direct life sciences investment to date – is a similarly positive indicator for the sector.
“This quarter shows continued improvement in funding confidence and deal flow right across the UK biotech sector,” says Chris Molloy, CEO of BIA.
“Its major headline is the strongest single quarter for UK life sciences venture funding in the last five years with over £2bn in venture capital placed. It has seen fundraising rounds from seed to Series D at world class valuations.
“Our collective focus must be to ensure that this momentum is maintained and that the proven returns our investors are making attract more institutional investors to back this sector with growth capital.”
